RWC-340B Submits Letter to HHS Regarding Drug Manufacturers Actions That Undermine the 340B Program & Letter to HRSA Regarding 340B Telehealth Policies

11 Sep 2020

Today, RWC-340B submitted to a letter to Secretary of the U.S. Department of Health and Human Services (HHS) Alex Azar requesting that HHS initiate enforcement actions, in the form of civil monetary penalties, against Eli Lilly and Company, Sanofi SA, Novartis Pharmaceuticals, and AstraZeneca PLC for failing to comply with their obligations under the 340B program to offer 340B pricing on drugs dispensed by contract pharmacies.  RWC-340B joins numerous other 340B stakeholders and Congressional leaders that have submitted letters to HHS regarding the recent actions taken by drug manufacturers.  The letters and statements can be found in this chart, which is posted on the RWC-340B website.

RWC-340B also sent a letter to the Health Resources and Services Administration (HRSA) regarding patient definition and telehealth.  Specifically, RWC-340B requested that HRSA:  1) clarify that the telehealth guidance that is currently published on the OPA Drug Pricing COVID-19 Resources Page is permanent guidance and will not expire at the end of the PHE; and 2) clarify details related to meeting patient definition requirements for telehealth services.

Both letters are attached to this email and can also be found on the RWC-340B website:  https://www.rwc340b.org/advocacy/.

Category: Congress

Comments are closed

Top